Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)

NCT00074737 is registered in ClinicalTrials.gov with Eleos, Inc. as lead sponsor.

NCT NCT00074737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00074737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Lead sponsor
Eleos, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
May 31, 2007
Enrollment
53 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia